Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Payables: 2019-2024

Historic Payables for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $9.6 million.

  • BridgeBio Pharma's Payables rose 39.95% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.0 million, marking a year-over-year increase of 74.90%. This contributed to the annual value of $9.6 million for FY2024, which is 9.73% down from last year.
  • Per BridgeBio Pharma's latest filing, its Payables stood at $9.6 million for FY2024, which was down 9.73% from $10.7 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Payables high stood at $11.9 million for FY2021, and its period low was $8.9 million during FY2020.
  • In the last 3 years, BridgeBio Pharma's Payables had a median value of $10.7 million in 2023 and averaged $10.6 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 32.86% in 2021, then fell by 9.73% in 2024.
  • BridgeBio Pharma's Payables (Yearly) stood at $8.9 million in 2020, then soared by 32.86% to $11.9 million in 2021, then fell by 2.74% to $11.6 million in 2022, then dropped by 7.81% to $10.7 million in 2023, then decreased by 9.73% to $9.6 million in 2024.